1 of 1
Story summary
- AbbVie has filed a lawsuit against the U.S. government seeking clearer eligibility guidelines for the 340B drug discount program.
- The company claims that current definitions allow hospitals to exploit loopholes, obtaining discounts for patients with minimal contact.
- AbbVie aims to restrict discounts to providers who have directly managed a patient's condition and seen them within the last 12 months.
- This lawsuit underscores ongoing tensions between drugmakers and healthcare providers over the program's implementation and transparency.
- The case is filed in the U.S. District Court for the District of Columbia.
